Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit

This article was originally published in The Tan Sheet

Executive Summary

The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to 
take stock of its relationship with Congress and to 
re-evaluate its organizational structure.
Advertisement

Related Content

FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
Tyler's Departure As FDA Chief Counsel Leaves Another Chair To Fill
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
FDA Unveils Plan To Boost Transparency To Industry
More FDA Transparency May Confuse Consumers, Stifle Competition - Industry
FDA Launches System To Track Performances of Its Offices
FDA Reorganization Elevates Scientific And Food Safety Priorities
Hamburg Discusses FDA Top Priorities At HELP Confirmation Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS104798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel